{"id":785160,"date":"2022-05-10T08:00:07","date_gmt":"2022-05-10T06:00:07","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/"},"modified":"2023-07-11T12:25:29","modified_gmt":"2023-07-11T10:25:29","slug":"verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/","title":{"rendered":"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress"},"content":{"rendered":"Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +\/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer\n\n\nCompany Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib\n\nBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.\n\n\n\u201cIn the first quarter of this year, we made significant progress
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +\/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Through 2025 to Support Continued Development […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-785160","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nVerastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +\/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Through 2025 to Support Continued Development […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-10T06:00:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-11T10:25:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"olomaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"olomaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\"},\"author\":{\"name\":\"olomaster\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\"},\"headline\":\"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress\",\"datePublished\":\"2022-05-10T06:00:07+00:00\",\"dateModified\":\"2023-07-11T10:25:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\"},\"wordCount\":2502,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\",\"name\":\"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-05-10T06:00:07+00:00\",\"dateModified\":\"2023-07-11T10:25:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\",\"name\":\"olomaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"caption\":\"olomaster\"},\"url\":\"https:\/\/bebeez.it\/en\/author\/olomaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/","og_locale":"en_US","og_type":"article","og_title":"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez","og_description":"Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +\/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Through 2025 to Support Continued Development […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/","og_site_name":"BeBeez","article_published_time":"2022-05-10T06:00:07+00:00","article_modified_time":"2023-07-11T10:25:29+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"author":"olomaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"olomaster","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/"},"author":{"name":"olomaster","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518"},"headline":"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress","datePublished":"2022-05-10T06:00:07+00:00","dateModified":"2023-07-11T10:25:29+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/"},"wordCount":2502,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/","name":"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-05-10T06:00:07+00:00","dateModified":"2023-07-11T10:25:29+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518","name":"olomaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","caption":"olomaster"},"url":"https:\/\/bebeez.it\/en\/author\/olomaster\/"}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/785160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=785160"}],"version-history":[{"count":1,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/785160\/revisions"}],"predecessor-version":[{"id":890373,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/785160\/revisions\/890373"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=785160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=785160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=785160"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=785160"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=785160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}